Literature DB >> 11850266

Accumulation of 10 fluoroquinolones by wild-type or efflux mutant Streptococcus pneumoniae.

Laura J V Piddock1, M M Johnson.   

Abstract

A method for measuring fluoroquinolone accumulation by Streptococcus pneumoniae was rigorously examined. The accumulation of ciprofloxacin, clinafloxacin, gatifloxacin, grepafloxacin, levofloxacin, moxifloxacin, norfloxacin, ofloxacin, sitafloxacin, and trovafloxacin in the presence and absence of either carbonyl cyanide m-chlorophenyl-hydrazone (CCCP) or reserpine was determined for two wild-type fluoroquinolone-susceptible capsulated S. pneumoniae strains (M3 and M4) and the noncapsulated strain R6. Two efflux mutants, R6N (which overexpresses PmrA) and a mutant of M4, M22 (no expression of PmrA), were also examined. Essentially, the fluoroquinolones fell into two groups. (i) One group consisting of ciprofloxacin, grepafloxacin, and norfloxacin accumulated to 72 to 92 ng/mg (dry weight) of cells in all strains. (ii) The remainder of the agents accumulated to 3 to 30 ng/mg (dry weight) of cells. With a decrease in hydrophobicity, there was a decrease in the concentration accumulated. With an increase in the molecular weight of the free form of each agent, there was also a decrease in the concentration accumulated. The strains differed in their responses to reserpine and CCCP. For the three fluoroquinolone-susceptible strains, only reserpine had a significant effect upon accumulation of moxifloxacin and clinafloxacin by M3 and showed no effect for the other agents and strains. For M3 and M4, CCCP enhanced the concentration of ciprofloxacin and norfloxacin accumulated, whereas for R6, the effect was only statistically significant for ofloxacin. Efflux mutant M22 accumulated less ciprofloxacin, gatifloxacin, and ofloxacin than M4 did. M22 accumulated more norfloxacin than M4 did. Reserpine and CCCP had variable effects as for the other strains. Differences in the accumulation of fluoroquinolones by R6 and R6N were highly dependent upon growth phase, and only for norfloxacin was there a significant difference between two strains.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11850266      PMCID: PMC127496          DOI: 10.1128/AAC.46.3.813-820.2002

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  19 in total

1.  Efflux and target mutations as quinolone resistance mechanisms in clinical isolates of Streptococcus pneumoniae.

Authors:  J Broskey; K Coleman; M N Gwynn; L McCloskey; C Traini; L Voelker; R Warren
Journal:  J Antimicrob Chemother       Date:  2000-04       Impact factor: 5.790

2.  Bactericidal activity of gemifloxacin and other quinolones against Streptococcus pneumoniae.

Authors:  I Morrissey; J T George
Journal:  J Antimicrob Chemother       Date:  2000-04       Impact factor: 5.790

3.  Mechanism of action of sparfloxacin against and mechanism of resistance in gram-negative and gram-positive bacteria.

Authors:  L J Piddock; M Zhu
Journal:  Antimicrob Agents Chemother       Date:  1991-11       Impact factor: 5.191

4.  A comparison of methods used for measuring the accumulation of quinolones by Enterobacteriaceae, Pseudomonas aeruginosa and Staphylococcus aureus.

Authors:  P G Mortimer; L J Piddock
Journal:  J Antimicrob Chemother       Date:  1991-11       Impact factor: 5.790

5.  A convenient assay for estimating the possible involvement of efflux of fluoroquinolones by Streptococcus pneumoniae and Staphylococcus aureus: evidence for diminished moxifloxacin, sparfloxacin, and trovafloxacin efflux.

Authors:  R Beyer; E Pestova; J J Millichap; V Stosor; G A Noskin; L R Peterson
Journal:  Antimicrob Agents Chemother       Date:  2000-03       Impact factor: 5.191

Review 6.  Penetration of lipophilic agents with multiple protonation sites into bacterial cells: tetracyclines and fluoroquinolones as examples.

Authors:  H Nikaido; D G Thanassi
Journal:  Antimicrob Agents Chemother       Date:  1993-07       Impact factor: 5.191

Review 7.  Mechanisms of fluoroquinolone resistance: an update 1994-1998.

Authors:  L J Piddock
Journal:  Drugs       Date:  1999       Impact factor: 9.546

8.  Potent antipneumococcal activity of gemifloxacin is associated with dual targeting of gyrase and topoisomerase IV, an in vivo target preference for gyrase, and enhanced stabilization of cleavable complexes in vitro.

Authors:  V J Heaton; J E Ambler; L M Fisher
Journal:  Antimicrob Agents Chemother       Date:  2000-11       Impact factor: 5.191

9.  Fluoroquinolone resistance in clinical isolates of Streptococcus pneumoniae: contributions of type II topoisomerase mutations and efflux to levels of resistance.

Authors:  D J Bast; D E Low; C L Duncan; L Kilburn; L A Mandell; R J Davidson; J C de Azavedo
Journal:  Antimicrob Agents Chemother       Date:  2000-11       Impact factor: 5.191

10.  Identification of a Streptococcus pneumoniae gene locus encoding proteins of an ABC phosphate transporter and a two-component regulatory system.

Authors:  R Novak; A Cauwels; E Charpentier; E Tuomanen
Journal:  J Bacteriol       Date:  1999-02       Impact factor: 3.490

View more
  24 in total

1.  Novel ciprofloxacin-resistant, nalidixic acid-susceptible mutant of Staphylococcus aureus.

Authors:  Laura J V Piddock; Yu Fang Jin; Mark A Webber; Martin J Everett
Journal:  Antimicrob Agents Chemother       Date:  2002-07       Impact factor: 5.191

2.  Preincubation of pneumococci with beta-lactams alone or combined with levofloxacin prevents quinolone-induced resistance without increasing intracellular levels of levofloxacin.

Authors:  Philippe Cottagnoud; Maggie Johnson; Marianne Cottagnoud; Laura Piddock
Journal:  Antimicrob Agents Chemother       Date:  2005-08       Impact factor: 5.191

Review 3.  Clinically relevant chromosomally encoded multidrug resistance efflux pumps in bacteria.

Authors:  Laura J V Piddock
Journal:  Clin Microbiol Rev       Date:  2006-04       Impact factor: 26.132

4.  New real-time PCR assay using locked nucleic acid probes to assess prevalence of ParC mutations in fluoroquinolone-susceptible Streptococcus pneumoniae isolates from France.

Authors:  Jean-Winoc Decousser; Imen Methlouthi; Patrick Pina; Anne Collignon; Pierre Allouch
Journal:  Antimicrob Agents Chemother       Date:  2006-04       Impact factor: 5.191

5.  Global transcriptome analysis of the responses of a fluoroquinolone-resistant Streptococcus pneumoniae mutant and its parent to ciprofloxacin.

Authors:  Estelle Marrer; A Tatsuo Satoh; Margaret M Johnson; Laura J V Piddock; Malcolm G P Page
Journal:  Antimicrob Agents Chemother       Date:  2006-01       Impact factor: 5.191

6.  Persistence of Mycoplasma hyopneumoniae in experimentally infected pigs after marbofloxacin treatment and detection of mutations in the parC gene.

Authors:  J Le Carrou; M Laurentie; M Kobisch; A V Gautier-Bouchardon
Journal:  Antimicrob Agents Chemother       Date:  2006-06       Impact factor: 5.191

7.  Involvement of the putative ATP-dependent efflux proteins PatA and PatB in fluoroquinolone resistance of a multidrug-resistant mutant of Streptococcus pneumoniae.

Authors:  Estelle Marrer; Karen Schad; Andreas T Satoh; Malcolm G P Page; Maggie M Johnson; Laura J V Piddock
Journal:  Antimicrob Agents Chemother       Date:  2006-02       Impact factor: 5.191

Review 8.  Distribution and physiology of ABC-type transporters contributing to multidrug resistance in bacteria.

Authors:  Jacek Lubelski; Wil N Konings; Arnold J M Driessen
Journal:  Microbiol Mol Biol Rev       Date:  2007-09       Impact factor: 11.056

9.  Spectrofluorimetric quantification of antibiotic drug concentration in bacterial cells for the characterization of translocation across bacterial membranes.

Authors:  Julia Vergalli; Estelle Dumont; Jelena Pajović; Bertrand Cinquin; Laure Maigre; Muriel Masi; Matthieu Réfrégiers; Jean-Marie Pagés
Journal:  Nat Protoc       Date:  2018-05-17       Impact factor: 13.491

Review 10.  Permeability barriers of Gram-negative pathogens.

Authors:  Helen I Zgurskaya; Valentin V Rybenkov
Journal:  Ann N Y Acad Sci       Date:  2019-06-04       Impact factor: 5.691

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.